Tarsons Products Limited (TARSONS) Fair Value & Analysis
Healthcare · IN · Market cap ₹14.2B
Fair value as of: Jul 3, 2026
From 16 valuation models · updated today
Share price +29.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹166.46 – ₹386.45 · fair‑value band ₹44.41 – ₹59.22 · the ₹266.60 price screens above the ₹59.22 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Tarsons Products Limited (TARSONS) currently trades at ₹266.60, while our model-based Fair Value estimate is ₹59.22 — implying the stock looks roughly 77.8% overvalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Tarsons Products Limited generated revenue of ₹4.2B at a net margin of 3.4%. Revenue grew 7.3% year over year. It earns a return on equity of 2.3%. Net debt stands at ₹3.7B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Tarsons Products Limited manufactures and trades in scientific plastic labware products in India and internationally. The company offers bottles and carboys; boxes and racks; cell cell culture ware, centrifuge ware, clamps and stands, cryoware, desiccator, tubings and connectors, filtration, genomics and PCR consumables, laboratory equipment and utilities, liquid handling consumables and reusables, magnetic stirrer bar, pp storage plates, sampling aids, vials and tubes, and volumetric reusables. It also provides general lab ware products. Its products are used in molecular biology, cell culture, genomics, proteomics, and immunology. Tarsons Products Limited was incorporated in 1983 and is headquartered in Kolkata, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Tarsons Products Limited reported revenue of ₹4.2B in FY2026 versus ₹3.0B in FY2022, a compound +8.9%/yr. Reported net income was ₹143M in FY2026, compounding −38.6%/yr from FY2022.
Is TARSONS fairly valued? → Check now
Similar stocks
6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.95 | $182.39 | -55% |
| EssilorLuxottica Société anonyme ESLOF | $205.86 | $114.90 | -44% |
| HOYA Corporation HOCPY | $162.33 | $101.00 | -38% |
| Medline Inc MDLN | $33.61 | $31.78 | -5% |
| Becton, Dickinson and Company BDX | $147.79 | $124.26 | -16% |
| Alcon Inc ALC | $66.11 | $36.99 | -44% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Tarsons Products Limited (TARSONS) undervalued?
What is the fair value of TARSONS?
What is the quality score of TARSONS?
What is the revenue of Tarsons Products Limited (TARSONS)?
What is the net profit margin of TARSONS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.